´ÜÀÏŬ·ÐÇ×ü ½ÃÀåÀº 2025³â 2,014¾ï 2,900¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 3,407¾ï ´Þ·¯·Î ¼ºÀåÇÏ¿© CAGRÀº 11.08%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸é¿ª°è´Â °¨¿°¿¡ ¹ÝÀÀÇÏ¿© ÀÚ¿¬ÀûÀ¸·Î Ç×ü¸¦ »ý¼ºÇÕ´Ï´Ù. ´ÜŬ·Ð Ç×ü´Â ¾ÏÀ̳ª °¨¿°°ú °°Àº ħÀÔÀÚ¿¡ ´ëÇÑ ½ÅüÀÇ ÀÚ¿¬ ¸é¿ª ü°è ¹ÝÀÀÀ» °ÈÇϵµ·Ï ¼³°èµÈ ºÐÀÚÀÔ´Ï´Ù. ´ÜÀÏŬ·ÐÇ×ü´Â ½ÇÇè½Ç¿¡¼ °³¹ßµÇ±â ¶§¹®¿¡ ÀΰøÀǾàǰÀ¸·Î ºÐ·ùµË´Ï´Ù. ´ÜÀÏŬ·ÐÇ×ü´Â °¨¿° °úÁ¤ÀÇ º»ÁúÀûÀÎ ºÎºÐÀ» ƯÀÌÀûÀ¸·Î Ç¥ÀûÀ¸·Î »ï±â ¶§¹®¿¡ ´Ù¸¥ À¯ÇüÀÇ °¨¿° Ä¡·áº¸´Ù ¿ì¼öÇÕ´Ï´Ù. ¹éÇ÷±¸¸¦ ƯÁ¤ ¹ÙÀÌ·¯½º ´Ü¹éÁú¿¡ ³ëÃâ½ÃÄÑ ¸¸µé¾îÁý´Ï´Ù. ÀÌÈÄ ÇØ´ç ¹ÙÀÌ·¯½º¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ç×ü¸¦ ´ë·® »ý»êÇϱâ À§ÇØ Å¬·Ðȵ˴ϴÙ. ´ÜÀÏŬ·ÐÇ×ü´Â ¿¡º¼¶óÃâÇ÷¿, ±¤°ßº´ µî ÀϺΠ¹ÙÀÌ·¯½º °¨¿°ÁõÀ» Ä¡·áÇϱâ À§ÇØ °³¹ßµÇ¾ú½À´Ï´Ù. ´ÜÀÏŬ·ÐÇ×ü´Â ¿¡º¼¶ó, ±¤°ßº´ µî ¿©·¯ ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ Ä¡·áÁ¦·Î °³¹ßµÇ¾î ¿ÔÀ¸¸ç, Äڷγª19 ÆÒµ¥¹Í ´ç½Ã ÀÓ»ó½ÃÇèÀ» ÅëÇØ ÁßÁõµµ °¨¼Ò¿¡ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾î ³Î¸® »ç¿ëµÇ¾ú½À´Ï´Ù.
´ÜÀÏŬ·ÐÇ×ü ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2020³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î ¾à 1,000¸¸ ¸íÀÌ ¾ÏÀ¸·Î ÀÎÇØ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Ï Ä¡·á¿¡´Â ´ÜÀÏŬ·ÐÇ×ü°¡ ¸Å¿ì À¯¿ëÇϱ⠶§¹®¿¡ Àú·ÅÇÑ °¡°ÝÀÇ ¾Ï Ä¡·áÁ¦¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª19 ÆÒµ¥¹Í ±â°£ µ¿¾È »õ·Î¿î ¾à¹° ¿ä¹ýÀ» °³¹ßÇϱâ À§ÇØ ¸¹Àº ´ÜÀÏ Å¬·Ð Ç×ü ÀÓ»ó½ÃÇèÀÌ ÁøÇàµÇ¾úÀ¸¸ç, Äڷγª19 Ä¡·á¿¡ ±ä±ÞÇÏ°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ±¤¹üÀ§ÇÑ Á¦Ç° ½ÂÀÎÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù.
´ÜÀÏŬ·ÐÇ×ü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå °³Ã´¿¡µµ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â º¹ÀâÇÏ°í ½É°¢ÇÑ Áúº´¿¡ ´ëÇÑ Æ¯À̼ºÀÌ ³ôÀº Ä¡·á¸¦ Á¦°øÇϱâ À§ÇÑ Á¶Ä¡ÀÔ´Ï´Ù. ¶ÇÇÑ, ´ÜÀÏŬ·ÐÇ×ü ½ÃÀåÀÇ ¼ºÀå ÀáÀç·ÂÀ» ÀÚ±ØÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
´ÜÀÏŬ·ÐÇ×ü ½ÃÀåÀÇ Áö¸®Àû Àü¸Á:
ºÏ¹Ì ±¹°¡µéÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ¹ß´ÞµÇ¾î ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ Áö¿ª¿¡¼´Â ´Ù·®ÀÇ ¾ËÄÚ¿Ã ¼·Ãë¿Í Á¤Å©Çªµå/ÆÐ½ºÆ®Çªµå ¹®È°¡ ºñ¸¸À» À¯¹ßÇϰí, ±¹¹ÎµéÀÌ ¾Ï¿¡ °¨¿°µÉ À§ÇèÀÌ ³ô½À´Ï´Ù.
¶ÇÇÑ, ¾Ï ȯÀÚ Ä¡·á¿¡ µµ¿òÀÌ µÇ´Â »õ·Î¿î ¹é½Å/ÀǾàǰÀÇ °³¹ßµµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Amneal Pharmaceuticals´Â º£¹Ù½ÃÁÖ¸¿ ¸¶¸®(Alymsys)¸¦ ¹Ì±¹¿¡¼ Ãâ½ÃÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¾àÀº º£¹Ù½ÃÁÖ¸¿(¾Æ¹Ù½ºÆ¾, Á¦³ÙÅØ)ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÔ´Ï´Ù. º£¹Ù½ÃÁÖ¸¿ ¸¶¸®(Bevacizumab Marie)´Â Mabxience°¡ °³¹ßÇß½À´Ï´Ù. ÀüÀ̼º ´ëÀå¾Ï, ºñÆíÆò»óÇÇ ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ 1Â÷ Ä¡·á, Áö¼Ó¼º, Àç¹ß¼º, ÀüÀ̼º ÀڱðæºÎ¾Ï, »óÇǼº ³¼Ò¾Ï, ³°ü¾Ï, ¿ø¹ß¼º º¹¸·¾ÏÀÇ Ä¡·á¿¡ À¯¿ëÇÕ´Ï´Ù.
The Monoclonal Antibodies Market is expected to grow from US$201.429 billion in 2025 to US$340.700 billion in 2030, at a CAGR of 11.08%.
The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule designed to enhance the body's natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore, they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the severity.
Monoclonal Antibodies Market Growth Drivers:
According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment, monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, many monoclonal antibodies' clinical trials took place in order to develop novel drug therapy, as well as a wide range of product approvals were made for emergency use in COVID-19 treatment.
With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibody therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.
Monoclonal Antibodies Market Geographical Outlook:
North American countries have a well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and putting the population at a high risk of being infected with cancer.
Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech). Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Monoclonal Antibodies Market Segmentation: